Skip to main content
MBRX logo

MBRX · Moleculin Biotech, Inc. · Investor Relations

Track MBRX — free
$7.74 -0.19 (-2.40%) At close · Nov 20 Q1 2025 earnings call transcript
Market Cap
$8.22M
Shares
1.06M
Volume · Nov 20 49.56K Avg daily vol (24 sessions) 44.57K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-18 Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
2026-11-16 Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
2026-11-12 Moleculin Secures Australian Patent for Annamycin Formulation Technology
2026-11-10 Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
2026-11-04 Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-10-30 Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
2026-10-20 Moleculin Announces Reverse Stock Split
2026-10-20 Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
2026-10-16 Moleculin Announces Reverse Stock Split
2026-10-07 Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
2026-09-29 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
2026-09-28 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
2026-09-25 Annamycin Turns "Cold" Pancreatic Tumors "Hot" in New Preclinical Data Presented at AACR
2026-09-23 Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
2026-09-14 Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
2026-08-14 Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
2026-07-31 Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
2026-06-30 Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
2026-06-05 Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
2026-05-29 Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
2026-05-15 Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
2026-05-08 Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
2026-03-23 Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
2026-03-19 Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
2026-01-12 Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Past events

Source: https://moleculin.com/investors/

Key facts CIK 1659617 CUSIP 60855D507 13F (30d) 32 filings 22 filers Visit website Investor relations